BRCA1 and neoplasm: Furthermore, higher PD‐L1 expression has been noted in patients with defective DDR genes including BRCA1,9 suggesting an interplay between DDR deficiency and the tumor/stromal immunophenotype, but does little to explain the >25% of patients with tumors that are resistant or refractory to platinum chemotherapy.10